Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 249

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1A
Chunk 249
---

if we fail to comply with Nasdaq listing requirements. In the event our common stock is delisted, we may seek to have our common stock
quoted on an over-the-counter marketplace, such as on the OTCQX. The OTCQX is not a stock exchange, and if our common stock trades on
the OTCQX rather than a securities exchange, there may be significantly less trading volume and analyst coverage of, and significantly
less investor interest in, our common stock, which may lead to lower trading prices for our common stock.

Any
potential delisting of our common stock from the Nasdaq may have materially adverse consequences to our stockholders, including:

    ●
    a
    reduced market price and liquidity with respect to our shares of common stock, which could make our ability to raise new investment
    capital more difficult;
  
    ●
    limited
    dissemination of market price of our common stock;
  
    ●
    limited
    news coverage;
  
    ●
    limited
    interest by investors in our common stock;
  
    ●
    volatility
    of the prices of our common stock, due to low trading volume;
  
    ●
    our
    common stock being considered a “penny stock,” which would result in broker-dealers participating in sales of our common
    stock being subject to the regulations set forth in Rules 15g-2 through 15g-9 promulgated under the Exchange Act;
  
    ●
    increased
    difficulty in selling our common stock in certain states due to “blue sky” restrictions; and
  
    ●
    limited
    ability to issue additional securities or to secure additional financing.

50

Sales
of substantial amounts of our securities in the public market could depress the market price of our common stock.

Our
common stock is listed for trading on the Nasdaq Capital Market. If our stockholders sell substantial amounts of our common stock in
the public market, or the market perceives that such sales may occur, the market price of our securities could fall and we may be unable
to sell our securities in the future.

Our
securities may experience extreme price and volume fluctuations, which could lead to costly litigation for us and make an investment
in us less appealing.

The
market price of our common stock may fluctuate substantially due to a variety of factors, including:

    ●
    the
    status and results of our clinical trials for our product candidate;

    ●
    our